Plus Therapeutics presents interim data from ReSPECT-GBM trial at neurosurgery meeting

Plus Therapeutics will present new interim data from its ReSPECT-GBM Phase 2 trial at the Congress of Neurological Surgeons Annual Meeting from September 28 to October 2 in Houston, Texas. This trial focuses on recurrent glioblastoma, a severe brain cancer. The company is testing Rhenium (186Re) Obisbemeda, a targeted radiotherapy designed to deliver high doses of radiation directly to brain tumors. This approach aims to improve patient outcomes compared to existing treatments, which offer limited benefits and significant side effects. Currently, there are no FDA-approved therapies that significantly extend life for patients with recurrent glioblastoma. The ReSPECT-GBM trial is supported by the National Cancer Institute, highlighting its potential importance in addressing this challenging condition.